Why was JUPITER stopped early?

The Data Safety Monitoring Board stopped the trial at a median 1.9 years of follow-up because the prespecified stopping boundary for efficacy was crossed. While this demonstrated strong benefit, early stopping can inflate the apparent size of the treatment effect, which is a common criticism of the trial.

Does JUPITER prove that lowering CRP prevents heart attacks?

No. Rosuvastatin lowered both LDL-C (by 50%) and hsCRP (by 37%) simultaneously. JUPITER cannot separate the contributions of each. The CANTOS trial (2017), using a pure anti-inflammatory drug (canakinumab), later confirmed that inflammation reduction alone reduces CV events.

Did the 2013 ACC/AHA guidelines incorporate JUPITER findings?

Yes. The 2013 guidelines introduced hsCRP ≥ 2.0 mg/L as a "risk enhancer" for patients in the borderline or intermediate ASCVD risk category. This language was retained and reinforced in the 2018 update.

What was the number needed to treat in JUPITER?

Over the median 1.9-year follow-up, the NNT to prevent one primary endpoint event was approximately 83. If extrapolated to 5 years (which requires assumptions), the NNT drops to roughly 25 to 30, though this extrapolation is not directly confirmed by the trial.

Did JUPITER find any safety concerns with rosuvastatin?

Yes. Physician-reported new-onset diabetes was significantly higher in the rosuvastatin group (3.0% vs. 2.4%, p = 0.01). This finding contributed to the FDA adding a diabetes warning to all statin drug labels in 2012. Muscle-related adverse events and liver enzyme elevations did not differ significantly between groups.

Can JUPITER results be applied to patients with established heart disease?

No. JUPITER excluded patients with known cardiovascular disease. Those patients already qualify for statin therapy under separate guideline recommendations based on secondary prevention data from trials like 4S and HPS.

Is hsCRP testing recommended for all adults?

No. Current ACC/AHA guidelines recommend hsCRP testing selectively, primarily when the 10-year ASCVD risk score places a patient in the borderline (5 to 7.5%) or intermediate (7.5, <20%) range and the statin decision is uncertain. Universal screening is not recommended.

How does JUPITER compare to HOPE-3?

HOPE-3 (2016) tested rosuvastatin 10 mg in a broader intermediate-risk population over 5.6 years and showed a significant reduction in CV events. HOPE-3 did not require elevated hsCRP for enrollment. Together, the two trials support statin use across a wide range of primary-prevention candidates.

Is rosuvastatin the only statin supported for CRP-based prescribing?

Rosuvastatin is the only statin with an FDA-approved indication specifically tied to elevated hsCRP. Other high-intensity statins (like atorvastatin 40 to 80 mg) lower CRP as well, but they were not tested in a dedicated CRP-selected population the way JUPITER tested rosuvastatin.

What JUPITER Actually Changes in Clinical Practice

Q: What was the primary endpoint of the JUPITER trial?

The primary endpoint was first occurrence of a major cardiovascular event: nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. Rosuvastatin 20 mg reduced this composite by 44% compared to placebo.

Q: How does JUPITER compare to HOPE-3?

HOPE-3 (2016) tested rosuvastatin 10 mg in a broader intermediate-risk population over 5.6 years and showed a significant reduction in CV events. HOPE-3 did not require elevated hsCRP for enrollment. Together, the two trials support statin use across a wide range of primary-prevention candidates.

Q: Is rosuvastatin the only statin supported for CRP-based prescribing?

Rosuvastatin is the only statin with an FDA-approved indication specifically tied to elevated hsCRP. Other high-intensity statins (like atorvastatin 40 to 80 mg) lower CRP as well, but they were not tested in a dedicated CRP-selected population the way JUPITER tested rosuvastatin.

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for What JUPITER Actually Changes in Clinical Practice Image: HealthRX.com clinical image

At a glance

| Parameter | Detail | |---|---| | N | 17,802 | | Intervention | Rosuvastatin 20 mg daily | | Comparator | Matching placebo | | Duration | Median 1.9 years (stopped early) | | Primary endpoint | First major cardiovascular event (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) | | Key result | HR 0.56 (95% CI 0.46, 0.69), 44% relative risk reduction (Ridker et al., NEJM 2008) |

The Enrollment Decision That Made This Trial Unique

Most statin trials before JUPITER enrolled patients with elevated LDL-C or established coronary disease. JUPITER explicitly excluded anyone with LDL-C ≥ 130 mg/dL. The median baseline LDL was 108 mg/dL. Instead, entry required hsCRP ≥ 2.0 mg/L, a threshold associated with vascular inflammation.

This meant the trial population looked "low risk" by traditional lipid criteria. About 41% had metabolic syndrome. The median age was 66 for men, 67 for women. Women comprised 38% of participants, a higher proportion than most prior statin megatrials. These weren't patients a 2006-era physician would have routinely prescribed a statin to (Ridker et al., NEJM 2008).

The Data Safety Monitoring Board halted the trial at a median follow-up of only 1.9 years because the prespecified stopping boundary for efficacy had been crossed. Early stopping matters for interpretation. It tends to inflate relative risk reductions. Critics raised this point immediately, and it remains the single most common methodological objection.

Results Beyond the Primary Endpoint

The 44% reduction in the composite primary endpoint broke down as follows:

| Outcome | Rosuvastatin | Placebo | HR (95% CI) | |---|---|---|---| | Primary composite MACE | 142 events | 251 events | 0.56 (0.46, 0.69) | | Myocardial infarction | 31 fatal/nonfatal | 68 | 0.46 (0.30, 0.70) | | Stroke | 33 | 64 | 0.52 (0.34, 0.79) | | Revascularization | 71 | 131 | 0.54 (0.41, 0.72) | | All-cause mortality | 198 | 247 | 0.80 (0.67, 0.97) | | Venous thromboembolism | 34 | 60 | 0.57 (0.37, 0.86) |

The VTE finding was unexpected. JUPITER was one of the first large trials to show a statin reducing venous clot risk. That result has been replicated in meta-analyses but has not entered routine prescribing decisions for VTE prophylaxis.

Rosuvastatin dropped LDL-C by 50% (median on-treatment LDL: 55 mg/dL) and hsCRP by 37%. Both reductions occurred simultaneously, making it impossible to attribute the clinical benefit to one mechanism alone (Ridker et al., NEJM 2008).

What the Guidelines Actually Changed

2013 ACC/AHA Cholesterol Guidelines

The 2013 ACC/AHA guidelines (Stone et al., JACC 2014) replaced LDL targets with a pooled-cohort-equation (PCE) risk calculator and four statin-benefit groups. JUPITER's influence appears in the "borderline risk" zone: for patients with a 10-year ASCVD risk between 5% and 7.5%, the guidelines list hsCRP ≥ 2.0 mg/L as a "risk enhancer" that can tip the decision toward statin therapy.

This was a direct consequence of JUPITER. Before the trial, hsCRP had no formal role in any major lipid guideline.

2018 ACC/AHA Multisociety Guideline Update

The 2018 update (Grundy et al., JACC 2019) kept hsCRP as a risk enhancer. For adults aged 40 to 75 with LDL-C 70 to 189 mg/dL and a 10-year ASCVD risk of 7.5% to <20% (the "intermediate risk" group), the guideline explicitly states that hsCRP ≥ 2.0 mg/L favors statin initiation when the clinician-patient discussion is otherwise uncertain.

Practically, this means a 55-year-old with LDL of 115 mg/dL, no diabetes, and a borderline PCE score who also has an hsCRP of 3.2 mg/L now has a guideline-endorsed reason to start moderate- or high-intensity statin therapy. Before JUPITER, that patient would have been told to diet and exercise.

European Society of Cardiology

The ESC has been more cautious. Its 2019 dyslipidemia guidelines (Mach et al., Eur Heart J 2020) acknowledge hsCRP as a risk modifier but do not incorporate it into the SCORE2 algorithm with the same weight the ACC/AHA framework does. European prescribing patterns shifted less in response to JUPITER than American ones.

What Actually Changed in Prescribing

Before JUPITER, rosuvastatin (Crestor) held roughly 10% of the US statin market. After publication in November 2008, AstraZeneca actively promoted JUPITER findings. Crestor prescriptions rose substantially through 2012, when it peaked as the second most-prescribed statin in the US (FDA label, rosuvastatin).

The FDA approved a new indication for rosuvastatin in February 2010: primary prevention of cardiovascular events in men ≥ 50 and women ≥ 60 with hsCRP ≥ 2 mg/L and at least one additional risk factor. This was the first statin indication tied to an inflammatory biomarker rather than an LDL threshold.

Generic rosuvastatin became available in 2016, making the cost argument largely irrelevant for current practice. The JUPITER-derived indication now applies to a commodity drug, not a branded one.

The Limitations That Still Matter

Early termination. Median follow-up was 1.9 years against a planned 4-year trial. The absolute risk reduction was 1.2 percentage points (NNT of about 83 over 1.9 years). Extrapolating that to 5 or 10 years requires assumptions about sustained benefit, which JUPITER cannot confirm. The HOPE-3 trial (2016) later showed rosuvastatin 10 mg reduced CV events over 5.6 years in an intermediate-risk population, partially filling that gap (Yusuf et al., NEJM 2016).

Confounded mechanism. Because rosuvastatin lowered both LDL and CRP simultaneously, JUPITER could not prove that reducing inflammation (independent of LDL lowering) prevents events. That question was answered later by the CANTOS trial (2017), which used canakinumab, a pure IL-1β inhibitor, and showed CV benefit without any LDL change. CANTOS validated the inflammatory hypothesis. JUPITER raised it (Ridker et al., NEJM 2008).

Population generalizability. JUPITER excluded patients with diabetes, prior CV events, or LDL ≥ 130 mg/dL. The trial population was healthier than most real-world primary-prevention candidates. Physicians should not extrapolate JUPITER results to patients with established atherosclerotic disease (those patients already qualify for statins on other grounds) or to patients with very low hsCRP and low LDL (who were excluded and may not benefit).

Adverse signals. Rosuvastatin-treated patients had a small but statistically significant increase in physician-reported diabetes (3.0% vs. 2.4%, p = 0.01). This finding, replicated across statin meta-analyses, accelerated the FDA's 2012 addition of diabetes risk to all statin labels. For most patients, the cardiovascular benefit outweighs the diabetes risk, but the tradeoff deserves a direct conversation, especially in patients already at high risk for type 2 diabetes.

Sponsor involvement. AstraZeneca funded the trial. Paul Ridker, the principal investigator, co-holds the patent on the hsCRP assay used for enrollment. These conflicts were disclosed. They do not invalidate the findings, but they explain why independent replication (HOPE-3, CANTOS) was so important for practice change.

Who Benefits Most From JUPITER's Findings Today

The patient profile that benefits most clearly:

Age 50 to 70
LDL-C between 70 and 130 mg/dL
No diabetes, no prior CV event
10-year ASCVD risk in the 5% to 15% range
hsCRP persistently ≥ 2.0 mg/L on repeat testing

For these patients, JUPITER provides the strongest evidence that statin therapy reduces events. The 2018 ACC/AHA guideline supports this prescribing decision.

Patients who fall outside this profile need a different evidence base. Patients with established ASCVD should be on statins regardless of hsCRP. Patients with very low hsCRP (<1.0 mg/L) and low ASCVD risk were not studied. Patients with isolated elevated CRP from non-cardiovascular causes (autoimmune disease, acute infection) should not have that value used for statin decision-making.

The Practical Takeaway for Clinicians

JUPITER did three things that still matter. First, it showed statins work in a population that traditional LDL-based criteria would have missed. Second, it gave hsCRP a formal place in cardiovascular risk assessment, even if that place is as a tiebreaker rather than a primary driver. Third, the diabetes signal it detected accelerated pharmacovigilance for the entire drug class.

What JUPITER did not do: it did not prove that lowering inflammation per se is the mechanism, it did not test lower statin doses, and it did not run long enough to define the 10-year benefit curve. For clinicians seeing a patient with borderline risk and elevated CRP, JUPITER is the reason they can write that prescription with guideline support, not a guess.

Frequently asked questions

›

References

Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. PubMed
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. PubMed
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. PubMed
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021-2031. PubMed
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. PubMed
Rosuvastatin calcium prescribing information. U.S. Food and Drug Administration. FDA Label